Efficacy and Safety of select Flavonoids for the Treatment of Uncomplicated SARS-CoV-2 COVID-19
Phase 2
Not yet recruiting
- Conditions
- Respiratory
- Registration Number
- PACTR202010537777617
- Lead Sponsor
- EMSKE Phytochem
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 200
Inclusion Criteria
Patients 18-80 y.o.presenting with positive PCR test for COVID-19.
Exclusion Criteria
Patients on chronic medications that require P450 enzyme to be uninhibited. (example - atorvastatin, blood thinners, heart arrhythmia medication)
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms do flavonoids target in SARS-CoV-2 viral replication pathways?
How do flavonoid-based therapies compare to standard-of-care treatments for mild-to-moderate COVID-19?
Which biomarkers correlate with improved clinical outcomes in flavonoid-treated SARS-CoV-2 patients?
What are the potential adverse events associated with high-dose flavonoid administration in respiratory viral infections?
How do flavonoids synergize with antiviral agents in preclinical models of SARS-CoV-2 infection?